Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 6/20 | 0.35 |
| ▸ | CES2 | O00748 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 8/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8062961 | 0.86 | FAAH (0.48) | CES1CES2FAAHLMNAMEN1 | |
| SCHEMBL835849 | 0.84 | FAAH (0.50) | CES1CES2FAAHLMNAMEN1 | |
| SCHEMBL6898362 | 0.84 | FAAH (0.50) | CES1CES2FAAHLMNAMEN1 | |
| SCHEMBL3422366 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL17425328 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CES1CES2FAAHHDAC3 | |
| SCHEMBL2885841 | 0.76 | ALDH1A1 (0.40) | ALDH1A1CES1CES2FAAHLMNA | |
| SCHEMBL5748551 | 0.76 | ALDH1A1 (0.48) | ALDH1A1CES1CES2FAAHHDAC3 | |
| SCHEMBL27581259 | 0.76 | ALDH1A1 (0.48) | ALDH1A1CES1CES2FAAHHDAC3 | |
| SCHEMBL11257758 | 0.75 | ALDH1A1 (0.52) | ALDH1A1CES1CES2HDAC3HDAC1 | |
| SCHEMBL16856433 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CES1CES2FAAHHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117154190-A | Mixed electrolyte and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2023-12-01 | — | — | CN | claimed |
| CN-115411365-A | Non-aqueous electrolyte and application thereof | 远景动力技术(江苏)有限公司 | 2022-11-29 | — | — | CN | claimed |
| US-8748046-B2 | Lithium-ion electrolytes with fluoroester co-solvents | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-06-10 | — | — | US | claimed |
| US-7550607-B2 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | AUSPEX PHARMACEUTICAL, INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20080305401-A1 | Lithium-ion electrolytes with fluoroester co-solvents | UNIVERSITY OF SOUTHERN CALIFORNIA | 2008-12-11 | — | — | US | claimed |
| EP-1594835-A4 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS INC (US) | 2007-05-02 | — | — | EP | claimed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | claimed |
| WO-2006012277-A2 | BIOCATALYTIC PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED PRAMIPEXOLE | AMR TECHNOLOGY, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| EP-1581465-A2 | BIOCATALYTIC PREPARATION OF ENANTIOMERICALLY ENRICHED AMINOPENTANENITRILE | PCBU Services, Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| US-20050026260-A1 | Enzymatic resolution of propylene glycol alkyl (or aryl) ethers and ether acetates | RESNICK SOL M (US) | 2005-02-03 | — | — | US | claimed |
| EP-1490501-A2 | ENZYMATIC RESOLUTION OF PROPYLENE GLYCOL ALKYL (OR ARYL) ETHERS AND ETHER ACETATES | Dow Global Technologies Inc. (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004058701-A2 | BIOCATALYTIC PREPARATION OF ENANTIOMERICALLY ENRICHED AMINOPENTANENITRILE | PCBU SERVICES, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040121435-A1 | Biocatalytic preparation of enantiomerically enriched aminopentanenitrile | PFIZER INC. | 2004-06-24 | — | — | US | claimed |
| WO-2003083126-A2 | ENZYMATIC RESOLUTION OF PROPYLENE GLYCOL ALKYL (OR ARYL) ETHERS AND ETHER ACETATES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-10-09 | — | — | WO | claimed |
| EP-1002123-A1 | ENZYMATIC KINETIC RESOLUTION OF AN INTERMEDIATE USEFUL FOR PREPARING SUBSTITUTED TRICYCLICS | SCHERING CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| US-6037166-A | MULTISTEP PROCESS USING HYDROLASE AND ACYLATING AGENT; OPTIONALLY CONVERTING UNDESIRED ISOMERS INTO RACEMATE BY HEATING AND RESUBJECTING TO PROCESS; FOR ANTIHISTAMINES AND INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-03-14 | — | — | US | claimed |
| WO-1998058073-A1 | ENZYMATIC KINETIC RESOLUTION OF AN INTERMEDIATE USEFUL FOR PREPARING SUBSTITUTED TRICYCLICS | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | claimed |
| US-H1679-H | Process for preparing an optically pure intermediate for a phosphonosulfonate soualene synthetase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-09-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | LSS, DHPS, CYP51A1 | ALDH1A1 1435/4885CES1 1016/4885CES2 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.